At what age does retinopathy of prematurity (ROP) typically stop being a concern?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

When ROP Stops Being a Concern

ROP screening can be safely discontinued when the infant reaches 45 weeks postmenstrual age without developing prethreshold ROP or worse, when retinal vessels progress into Zone 3 without prior Zone 2 disease, or when complete retinal vascularization occurs. 1, 2

Age-Based Discontinuation Criteria

Postmenstrual Age Threshold:

  • Screening can stop at 45 weeks postmenstrual age if the infant has not developed prethreshold ROP or worse. 2 This represents the primary age-based cutoff where the risk of vision-threatening ROP has essentially passed.

Gestational Age Considerations:

  • Infants born at greater than 32 weeks gestational age do not develop type 1 ROP and never require screening in the first place. 3
  • No infant with gestational age >32 weeks at birth developed type 1 ROP in a large cohort of over 11,000 infants. 3

Anatomic Criteria for Discontinuation

Zone-Based Progression:

  • ROP that is regressing with vessels passed into Zone 3 on at least two sequential examinations is extremely unlikely to progress to threshold ROP. 4, 1, 5 This is one of the safest indicators that screening can cease.
  • Infants whose vessels remain in Zone 1 or Zone 2 are at higher risk and require continued monitoring every 1-2 weeks. 4, 1

Complete Vascularization:

  • Full retinal vascularization indicates screening can be discontinued, as the developmental window for ROP has closed. 1, 2

Timing of Peak Risk

When ROP Develops:

  • Type 1 ROP is first diagnosed at a median postmenstrual age of 36 weeks (range 30-46 weeks). 3
  • The mean postnatal age at diagnosis remains relatively consistent at 11-13 weeks across different gestational ages. 3
  • In 99% of infants, retinal conditions indicating risk of poor outcome are not observed before 31 weeks postmenstrual age or 4 weeks chronologic age. 2

Critical Pitfalls in Discontinuing Surveillance

Home Discharge Concerns:

  • The greatest risk occurs when infants with unresolved ROP in Zone 1 or 2 are discharged home and miss follow-up appointments. 4 This represents a tragedy where successful NICU graduation leads to preventable blindness.
  • Parents cannot typically provide close oxygen control at home without extensive support, which may worsen ROP progression. 4

Oxygen Management:

  • Once past the age of oxygen-induced retinopathy risk (typically after vessels reach Zone 3), target oxygen saturation of 95% or higher is recommended. 4, 5
  • The STOP-ROP trial found that saturation targets of 96-99% do not increase risk of ROP progression in infants with pre-threshold disease. 4

Practical Algorithm

  1. Continue screening if:

    • Infant is <45 weeks postmenstrual age AND has any ROP in Zone 1 or 2
    • Any prethreshold or threshold ROP is present regardless of age
  2. Discontinue screening when ANY of these occur:

    • 45 weeks postmenstrual age reached without prethreshold ROP 2
    • Vessels progress into Zone 3 on two consecutive exams without prior Zone 2 disease 4, 2
    • Complete retinal vascularization documented 1, 2
  3. Never screen:

    • Infants born >32 weeks gestational age 3
    • Infants 29-37 weeks with medically stable course (though conservative approach screens all <32 weeks) 1

References

Guideline

Timing of First ROP Screening Examination in Newborns

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment and Management of Retinopathy of Prematurity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.